Physician profile
Wei Shen
NPI 1881885747
$3,830.97
in general payments reported to CMS, 2019-2025
31 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.82 · 2020: $395 · 2021: $671 · 2022: $344 · 2023: $461 · 2024: $1,037 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.95 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $469.26 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $395.45 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $365.82 | 2020-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.80 | 2023-2025 | Jardiance |
| Pfizer INC. | $327.22 | 2020-2025 | |
| Abbvie INC. | $226.88 | 2021-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $223.42 | 2023-2025 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $216.00 | 2019-2022 | |
| Exact Sciences Corporation | $207.26 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $187.80 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $132.18 | 2023-2025 | Xarelto, Spravato |
| Idorsia Pharmaceuticals US INC | $111.74 | 2022-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $67.85 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $66.61 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $65.49 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.35 | 2025 | Repatha |
| Sanofi Pasteur INC. | $50.11 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.40 | 2023-2024 | |
| Allergan, INC. | $36.01 | 2020 | |
| Philips North America LLC | $33.88 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $23.85 | 2025 | Giapreza |
| Inspire Medical Systems, INC. | $21.67 | 2024 | Inspire |
| Tetraphase Pharmaceuticals, INC. | $21.23 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.85 | 2024 | Voquezna |
| Eisai INC. | $19.65 | 2020 | |
| Dexcom, INC. | $18.35 | 2021 | |
| Esperion Therapeutics, INC. | $16.70 | 2025 | Nexletol |
| Hologic Sales and Service, LLC | $15.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.